ARTICLE | Company News

Abbott, Genelabs Technologies Inc, Merck Research Laboratories other research news

January 16, 1995 8:00 AM UTC

Results from patients in Phase I/IIA trials were used to calculate the rate of replacement of wild-type virus by drug-resistant variants, and the rate of viral replication. As published in Nature by the companies and their collaborators at university and government laboratories, the findings show that asymptomatic patients can harbor millions of genetically distinct variants of HIV.

According to an accompanying commentary, this means that monotherapy cannot be expected to stop AIDS, and that only a combination of drugs, instituted early, has any hope of checking the infection. ...